BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38289126)

  • 1. NT5DC2 knockdown suppresses progression, glycolysis, and neuropathic pain in triple-negative breast cancer by blocking the EGFR pathway.
    Sang R; Yu X; Xia H; Qian X; Yong J; Xu Y; Sun Y; Yao Y; Zhou J; Zhuo S
    Mol Carcinog; 2024 Apr; 63(4):785-796. PubMed ID: 38289126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling.
    Qiao L; Dong C; Jia W; Ma B
    Cell Signal; 2023 Dec; 112():110922. PubMed ID: 37827343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
    Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
    J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
    Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
    Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma.
    Li KS; Zhu XD; Liu HD; Zhang SZ; Li XL; Xiao N; Liu XF; Xu B; Lei M; Zhang YY; Shi WK; Cao MQ; Xu YF; Tang ZY; Sun HC
    Cell Death Dis; 2020 May; 11(5):335. PubMed ID: 32382041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
    Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
    Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circ-CSNK1G1 promotes cell proliferation, migration, invasion and glycolysis metabolism during triple-negative breast cancer progression by modulating the miR-28-5p/LDHA pathway.
    Zan X; Li W; Wang G; Yuan J; Ai Y; Huang J; Li Z
    Reprod Biol Endocrinol; 2022 Sep; 20(1):138. PubMed ID: 36109751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NT5DC2 knockdown inhibits colorectal carcinoma progression by repressing metastasis, angiogenesis and tumor-associated macrophage recruitment: A mechanism involving VEGF signaling.
    Zhu Z; Hou Q; Guo H
    Exp Cell Res; 2020 Dec; 397(1):112311. PubMed ID: 32991874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
    Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
    FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CircWHSC1 regulates malignancy and glycolysis by the miR-212-5p/AKT3 pathway in triple-negative breast cancer.
    Ding L; Xie Z
    Exp Mol Pathol; 2021 Dec; 123():104704. PubMed ID: 34624276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
    Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT1 is required for the survival of triple-negative breast cancer cells via potentiation of EGFR activity.
    Liu H; Ertay A; Peng P; Li J; Liu D; Xiong H; Zou Y; Qiu H; Hancock D; Yuan X; Huang WC; Ewing RM; Downward J; Wang Y
    Mol Oncol; 2019 Sep; 13(9):1874-1886. PubMed ID: 31199048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.
    Wang JJ; Zou JX; Wang H; Duan ZJ; Wang HB; Chen P; Liu PQ; Xu JZ; Chen HW
    Acta Pharmacol Sin; 2019 Aug; 40(8):1067-1075. PubMed ID: 30670815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential.
    Pelicano H; Zhang W; Liu J; Hammoudi N; Dai J; Xu RH; Pusztai L; Huang P
    Breast Cancer Res; 2014 Sep; 16(5):434. PubMed ID: 25209360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression.
    Bi J; Wu Z; Zhang X; Zeng T; Dai W; Qiu N; Xu M; Qiao Y; Ke L; Zhao J; Cao X; Lin Q; Chen XL; Xie L; Ouyang Z; Guo J; Zheng L; Ma C; Guo S; Chen K; Mo W; Fu G; Zhao TJ; Wang HR
    Nat Commun; 2023 Apr; 14(1):2342. PubMed ID: 37095176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect.
    Shi Y; Zhang Y; Ran F; Liu J; Lin J; Hao X; Ding L; Ye Q
    Cancer Lett; 2020 Dec; 495():53-65. PubMed ID: 32946964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.